PTO/SB/30 (09-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Request For Continued Examination (RCE) **Transmittal**

Address to: M\$ RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

<u> </u>	
Application Number	09/900,766
Filing Date	July 6, 2001
First Named Inventor	Goran Forsberg
Art Unit	1645
Examiner Name	P. A. Duffy
Attorney Docket Number	HO-P02188US0


This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June

8, 1995, or to any design application.	
1. Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).	
a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.	
i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on	
ii. Other	
b. x Enclosed	
i. X Amendment/Reply iii. Information Disclosure Statement (IDS)	
ii. Affidavit(s)/Declaration(s) iv. Other	
2. Miscellaneous	
a. Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)	
b. Other 3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.	
a. The Director is hereby authorized to charge the following fees, or credit any overpayments, to	
Deposit Account No.	
i. X RCE fee required under 37 CFR 1.17(e)	
ii. X Extension of time fee (37 CFR 1.136 and 1.17)	
iii. Other	
b. X Check in the amount of \$ enclosed	
c. Payment by credit card (Form PTO-2038 enclosed)	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED	
Name (Print/Type) Melissa W, Acosta Registration No. (Attorney/Agent) 45,872	
Signature Date June 2, 2004	
1	

Request for Continued Examination Transmittal

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER509328273US, in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown

Dated: June 2, 2004



Docket No.: HO-P02188US0

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Goran Forsberg et al.

Confirmation No.: 7699

Application No.: 09/900,766

Art Unit: 1645

Filed: July 6, 2001

Examiner: P. A. Duffy

For: NOVEL ENGINEERED SUPERANTIGEN FOR

HUMAN THERAPY

RCE AMENDMENT (37 C.F.R. SECTION 1.114)

MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action dated December 4, 2003 and the Advisory Action dated April 19, 2004, please amend the above-identified U.S. patent application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 6 of this paper.